Thx Kat to you & Riz.....also you said: " tropism changes
Thx Kat to you & Riz.....also you said: " tropism changes from CCR5 entry of HIV to CXCR4?"
THAT....is the comparison from years ago in Cytodyn presentation i could not remember terminology, etc...
But i knew that was not the "4" being referenced in the CD4 + T cells as "resting"....& key to resevoir clearing.
So yea...Nov. 2021 was mainly focused on designing a good CCR5 RO test
But Vs. placebo we had SIGNIFICANTLY better CD4+
We know patients lived around 7 yrs plus.
All sounding very similar to mTNBC / CTC due to latching CD4+ CCR5 receptor
Appreciate it !!....now it's all a clear picture for me
4
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Key Disclosure on Voting Rights and Shares As a reputable leader in stationery and consumer products, BIC is committed to transparency. Recently, they provided crucial insights into their corporate structure, particularly regarding the total number of voting rights and shares. This disclosure highlights the ongoing dedication towards maintaining clear communication with...
Continue Reading
AGCO (NYSE: AGCO) is strutting its stuff at the 2026 Commodity Classic in San Antonio from February 25-27. Picture this: over 24,000 square feet jam-packed with cutting-edge agricultural machinery aimed at farmers who want to boost their operations. Yeah, the buzz is all about showcasing their big guns like Fendt®, Massey Ferguson®, and PTx™—but dig deeper into...
Continue Reading
Revolutionizing Healthcare Marketing with Ignite Pulse Solutions In the shifting landscape of healthcare marketing, WebMD Ignite introduces a significant enhancement aimed at assisting health systems in thriving amidst the challenges posed by AI and budget constraints. Presenting Ignite Pulse™, this groundbreaking solution offers a comprehensive growth strategy designed...
Continue Reading
Eupraxia Pharmaceuticals Expands Leadership Team Eupraxia Pharmaceuticals Inc. (TSX: EPRX) (NASDAQ: EPRX), known for its innovative approaches in drug delivery technology, has recently announced two significant additions to its leadership. Dr. Amanda Malone has been appointed as the Chief Operating and Scientific Officer, alongside Dr. Rahul Sarugaser as Executive Vice...
Continue Reading
Illumina's Latest Developments in Oncology In an exciting development, Illumina Inc. (NASDAQ: ILMN) has announced a significant expansion in its clinical oncology portfolio. This move aims to set a new standard of care and enhance access to precision therapies through advanced genomic profiling. Following the recent FDA approval of Illumina's TSO Comprehensive test, the...
Continue Reading
